首页> 外文期刊>Immunologic Research: A Selective Reference to Current Research and Practice >T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract.
【24h】

T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract.

机译:T细胞介导的肿瘤免疫监视和上消化道癌中B7共抑制分子的表达。

获取原文
获取原文并翻译 | 示例
           

摘要

Tumorigenesis can induce adaptive T-cell-mediated immune responses against malignant cells. Such cellular immune responses are actively suppressed by cancer cells via mechanisms of immune tolerance. We studied T-cell responses against tumor growth by examining tumor-infiltrating lymphocytes (TILs) in upper gastrointestinal (GI) cancers. The number of T-bet(+) TILs correlates with better survival of esophageal cancer patients. Using well-defined mouse models, we have further shown that T-bet and Eomes are both required for the adaptive anti-tumor immunity by regulating T-cell trafficking into the tumor tissue and their effector functions inside the tumor microenvironment. In order to gain further insight into the tumor immune microenvironment in the upper GI cancer, we have also studied expression levels of co-inhibitory molecules such as B7-H1/PD-L1 and B7-H4 in tissue specimens of esophageal and gastric cancers. These inhibitory B7 molecules were expressed at high but variable levels by cancer cells. The overexpression of these molecules correlates with poor clinicopathological parameters and shorter patient survival time. The number of CD3(+) and CD8(+) TILs correlates inversely with expression levels of B7-H4 in samples from esophageal cancer, supporting a role of active immune suppression by inhibitory B7 molecules in the tumor microenvironment. In addition, TILs show functional exhaustion and express high levels of PD-1 and Tim-3. We propose that metabolic competition mediated by phosphatidylinositol 3-kinases (PI3Ks) characterizes the immune suppression within cancer tissues. Future tumor vaccine design should combine blockade of B7 inhibitory molecules and enhancement of T-bet and Eomes levels within the tumor microenvironment.
机译:肿瘤发生可以诱导针对恶性细胞的适应性T细胞介导的免疫反应。癌细胞通过免疫耐受机制积极抑制这种细胞免疫应答。我们通过检查上消化道(GI)癌症中的肿瘤浸润淋巴细胞(TIL)研究了针对肿瘤生长的T细胞反应。 T-bet(+)TIL的数量与食管癌患者的更好生存相关。使用定义明确的小鼠模型,我们进一步表明,T-bet和Eomes都是通过调节T细胞向肿瘤组织中的运输及其在肿瘤微环境中的效应子功能,对适应性抗肿瘤免疫所必需的。为了进一步了解上消化道癌中的肿瘤免疫微环境,我们还研究了食管癌和胃癌组织标本中共抑制分子如B7-H1 / PD-L1和B7-H4的表达水平。这些抑制性B7分子在癌细胞中以高水平但可变的水平表达。这些分子的过表达与不良的临床病理学参数和较短的患者存活时间有关。 CD3(+)和CD8(+)TIL的数量与食管癌样品中B7-H4的表达水平成反比,从而支持了肿瘤微环境中抑制性B7分子的主动免疫抑制作用。此外,TIL显示功能衰竭,并表达高水平的PD-1和Tim-3。我们建议由磷脂酰肌醇3-激酶(PI3Ks)介导的代谢竞争表征癌症组织内的免疫抑制。未来的肿瘤疫苗设计应结合B7抑制分子的阻断和肿瘤微环境中T-bet和Eomes水平的提高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号